Journal of Invasive and Non-Invasive Cardiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Journal of Invasive and Non-Invasive Cardiology (2023) Volume 6, Issue 3

Stem cells in the treatment of acute myocardial infarction

Mueller Hamm *

Department of Non-Invasive Cardiology, University of Melbourne, Parkville, Australia

*Corresponding Author:
Mueller Hamm
Department of Non-Invasive Cardiology,
University of Melbourne
Parkville, Australia
E-mail: hamm.mueller@urmia.ac.ir

Received:15-May-2023, Manuscript No. AAINIC-23-99680;Editor assigned: 22-May-2023, PreQC No. AAINIC-23-99680(PQ);Reviewed:05-Jun-2023, QC No. AAINIC-23-99680;Revised:09-Jun-2023, Manuscript No. AAINIC-23-99680(R); Published:16-Jun-2023, DOI: 10.35841/ aajidmm-6.3.149

Citation: Mueller Hamm. Stem cells in the treatment of acute myocardial infarction. J Invasive Non-invasive Cardiol. 2023;6(3):149

 

Visit for more related articles at Journal of Invasive and Non-Invasive Cardiology

Introduction

Stem cells have emerged as a promising avenue for the treatment of acute myocardial infarction (AMI). AMI, commonly known as a heart attack, is a serious medical condition in which the blood flow to the heart is blocked, resulting in damage to the heart muscle. It is a leading cause of death worldwide, and conventional treatments such as medications and surgeries have limitations. Stem cells, on the other hand, have the potential to regenerate damaged tissues, and numerous studies have shown promising results in the use of stem cells in the treatment of AMI [1].

In the context of AMI, stem cells have the potential to regenerate damaged heart tissue, reduce scar formation, and improve heart function. Several clinical trials have been conducted to evaluate the safety and efficacy of stem cell therapy for AMI. These trials have used different types of stem cells, including bone marrow-derived stem cells, mesenchymal stem cells, and cardiac stem cells. One of the earliest clinical trials to investigate the use of stem cells in the treatment of AMI was the REPAIR-AMI trial, which was published in 2006. This trial enrolled 204 patients with AMI and randomized them to receive either bone marrow-derived stem cells or a placebo. The results showed that the group that received stem cells had a significant improvement in left ventricular ejection fraction (LVEF) compared to the placebo group. LVEF is a measure of how well the heart is pumping blood [2].

Since then, numerous other clinical trials have been conducted, and the results have been largely positive. The mechanism of action of stem cell therapy in the context of AMI is not fully understood, but it is believed to involve several factors. One of the key mechanisms is the ability of stem cells to differentiate into various cell types in the heart, including cardiomyocytes, which are the cells that make up the heart muscle. Stem cells can also release various growth factors and cytokines that promote tissue repair and regeneration. Additionally, stem cells can reduce inflammation and apoptosis (cell death) in the heart tissue, which can improve heart function [3].

Treatments for coronary artery diseases:

Despite the promising results of stem cell therapy for AMI, there are still several challenges that need to be addressed. One of the major challenges is the optimal source of stem cells. Bone marrow-derived stem cells have been the most commonly used type of stem cells in clinical trials, but other types of stem cells, such as cardiac stem cells and mesenchymal stem cells, have also shown promise. It is not clear which type of stem cells is the most effective, and more research is needed to determine the optimal source. Another challenge is the optimal timing and route of administration of stem cells. It is not clear when is the best time to administer stem cells after a heart attack, and whether the route of administration (e.g., intravenous, intracoronary, or direct injection into the heart tissue) affects the efficacy of the treatment. Some studies have suggested that earlier administration of stem cells is associated with better outcomes, but more research is needed to confirm this and to determine the optimal timing and route of administration [4].

Additionally, there are concerns about the safety of stem cell therapy. While stem cells have shown promising results in clinical trials, there have also been reports of adverse events, such as arrhythmias, bleeding, and infections. More research is needed to determine the long-term safety of stem cell therapy and to identify strategies to minimize the risks of adverse events. Despite these challenges, stem cell therapy has the potential to revolutionize the treatment of AMI. It offers a promising alternative to conventional treatments, which have limitations and can have significant side effects. Stem cell therapy has shown promising results in improving heart function and reducing the incidence of adverse events in patients with AMI [5].

Conclusion

Stem cell therapy has emerged as a promising avenue for the treatment of acute myocardial infarction. Clinical trials have shown that stem cell therapy can improve heart function, reduce scar formation, and reduce the incidence of adverse events in patients with AMI. However, there are still several challenges that need to be addressed, including the optimal source, timing, and route of administration of stem cells, as well as the safety and cost of the treatment. More research is needed to address these challenges and to further evaluate the safety and efficacy of stem cell therapy for AMI. Nonetheless, the potential benefits of stem cell therapy make it an exciting area of research for the treatment of this serious medical condition.

 

References

  1. Shah AS, Griffiths M, Lee KK, etal.. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: Prospective cohort study. Br Med J. 2015;350.

    2. Indexed at, Google Scholar, Cross Ref

  2. Yeh RW, Sidney S, Chandra M,et al. Population trends in the incidence and outcomes of acute myocardial infarction . N Engl J Med. 2010;362(23):2155-65.

    3. Indexed at, Google Scholar, Cross Ref

  3. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care Eur Heart J. 2010;31(18):2197-204.

    4. Indexed at, Google Scholar, Cross Ref

  4. Kociol RD, Pang PS, Gheorghiade M, et al. Troponin elevation in heart failure: Prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56(14):1071-8.

    5. Indexed at, Google Scholar, Cross Ref

  5. Zimetbaum PJ, Josephson ME.Use of the electrocardiogram in acute myocardial infarction . N Engl J Med. 2003;348(10):933-40.

    6. Indexed at, Google Scholar, Cross Ref

Get the App